1

CURRICULUM VITAE Name: Shalina Gupta-Burt, M.D. Contact Data: shalinaburt@gmail.com 312-618-3884 cell EDUCATION Undergraduate/Medical School: 08/151978- 05/31/1984 University of Missouri-Kansas City School of Medicine 2411 Holmes St, Kansas City, MO 64108 Combined Baccalaureate/Medical Degree Program

Degrees: Bachelor of Arts (cum laude) in biology and chemistry Medical Degree

Post Graduate Training: 07/01/1984- 06/30/1985 Transitional Internship

Michigan State University Blodgett Medical Center-St. Mary’s Medical Center

1840 Wealthy St SE, Grand Rapids, MI 49503

07/01/1985-06/30/1987 Internal Medicine Residency

Baylor College of Medicine Clinical Investigator Pathway Texas Medical Center, Houston, TX

07/01/1988-12/31/1988 Chief Medical Resident/Clinical Instructor

Baylor College of Medicine The Methodist Hospital Houston, TX

08/15/1987-06/30/1988 Biotechnology Research Fellowship 01/01/1989-06/15/1990 National Cancer Institute

Division of Cancer Etiology Laboratory of Cellular Carcinogenesis and Tumor Promotion Bldg 37 Bethesda, MD

07/01/1990-06/30/1992 Medical Oncology Fellowship

National Cancer Institute Division of Cancer Treatment Medical Oncology Branch Bldg 10 Bethesda, MD

07/01/1991-06/30/1994 Radiation Oncology Residency

National Cancer Institute Division of Cancer Treatment Radiation Oncology Branch

2

Bldg 10 Bethesda, MD

07/05/1994-06/30/1995 Radiation Oncology Research Fellowship National Cancer Institute Division of Cancer Treatment Radiation Oncology Branch Division of Cancer Etiology Laboratory of Cellular Carcinogenesis and Tumor Promotion Bethesda, MD

MILITARY SERVICE 03/25/1991- 06/30/1994 Lieutenant Commander, Active Duty, Commission Corps,

Public Health Service BOARD CERTIFICATIONS 1989 Internal Medicine (ABIM) 1993 Medical Oncology (ABIM) 1995 Radiation Oncology (ABR) 1999 Recertification in Radiation Oncology 2009 Recertification in Medical Oncology 2010 Recertification in Radiation Oncology 2017 Hospice and Palliative Care (ABR/ABIM) ACTIVE MEDICAL LICENSE

2004 State of Kansas 2004 State of Missouri

Hospital Medical Staff Appointments: See Supplement A Employment/Appointment History 02/12/2013-present Medical and Radiation Oncology, LLC 02/28/2013-01/05/2018 Lawrence Cancer Center Precision Cancer Center Independent Contractor Lawrence Radiation Oncology 330 Arkansas Street Suite 120 Lawrence, KS 66044 06/30/2015-12/31/2017 Director-Oncology Services Ransom Memorial Hospital Ottawa, KS 05/03/2014-12/31/2017 Advanced Radiation Center ION/SightLine Oncology Services

3

Independent Contractor 6427 W. 119th

Overland Park, KS 66209 02/25/2010-12/31/2012 HCA Medical Oncology Associates/Midwest Cancer Care Employed Physician Medical and Radiation Oncology

Menorah Medical Center 12140 Nall Avenue Suite 200 Overland Park, KS 66209

08/16/2004-02/16/2010 Kansas City Cancer Center Radiation Oncology Private Practice-Partner South Office 1000 East 101st Terrace

Kansas City, MO 64131 04/2005-06/2012 Clinical Associate Professor

University of Kansas Medical Center Department of Radiation Oncology

07/05/1995-08/15/2004 RUSH-Presbyterian-St. Luke's Medical Center

RUSH University Associate Professor

Department of Radiation Oncology Chicago, IL

1996-2004 Assistant Professor

RUSH University /RUSH Cancer Institute Department of Medicine Section of Hematology/Oncology

1995-2001 Program Director, Radiation Oncology RUSH University Department of Radiation Oncology Chicago, IL

Departmental Committees/Programs: 1996-2001 Chair-Education Committee

1996-1998 Member-Quality Assurance Committee 1996-1997 Member-Equipment and Space Committee 1997-1998 Member-Ad Hoc Committee-Total Body Irradiation Technique Development 1997-1998 Chair-Ad Hoc Committee-Total Skin Electron Beam Technique Development

Course Director: 1999-MPH 542- Radiation Oncology 2000-Preceptor-Pharmacology Doctorate Residency Course in Radiation Oncology

2000-Symposia Chair, “A Look Back: A Century of Physics Applied to Radiation Oncology in Illinois”, A symposium honoring Lawrence Lanzl, Ph.D. June 21, 2000 2004-Medical Physics for the Student-High School, Northside College Prep High School-2004

4

2006-Didactic Lymphoma Lecture Course-University of Kansas

Faculty Committees: 1995-1996 Tumor Committee

1996-2001 Graduate Medical Education Committee 2000- Chair, Diagnostic Radiology Program GME Review Subcommittee 2000- Chair, Neuro-radiology Fellowship Program GME Review Subcommittee

1999- Chair, Med-Peds Program GME Review Subcommittee 1998- Member, Pathology Program GME Review Subcommittee 1996- Member Internal Review of Radiation Oncology Residency Program GME Subcommittee

1996-2004 Medical Student Academic Advisory Board 1996-2004 Member-Comprehensive Breast Center 1996-2004 Member-Cutaneous T-Cell Lymphoma Research Group 1996-2004 Lymphoma Research Group 1997-2005 Co-Chair Locally Advanced Breast Cancer Research Group 2002-2004 West Side Lung Cancer Group Subcommittee Chair: Combined Modality Treatment Section 2003-2004 Selection Committee Member for the Chairman of Radiation Oncology

Advisory Committees: 1996-2004 Chairman’s Advisory Committee-Department of Radiation Oncology

2002-2006 American College of Surgeons Oncology Group Radiation Oncology Committee

2003-2004 RUSH Cancer Strategic Task Force Committee Subcommittee Co-Chair- Lung Cancer Subcommittee Co-Chair- Head and Neck Cancer Member-Breast Cancer Committee

Member-Lymphoma Committee KCCC Committee Appointments: 2005-2010 Imaging Pathways Committee

2005- 2010 Research Committee US Oncology Network Committee Appointments;

2006- 2010 Radiation Oncology Research Committee 2006-2010 Radiation Oncology Pathways Committee

KCCC Research; 2008-2010 Principal Investigator-USON RTOG PILOT Program site Kansas City Cancer

Center-South HCA Midwest Cancer Care Committee Appointments: 2010-2012 Menorah Breast Cancer Advisory Committee 2010-2012 OPRMC Breast Advisory Committee 2010-2012 Oncology Strategy Council Midwest Cancer Care Lead-Radiation Oncology 2011-2012 Sara Cannon Cancer Institute-HCA National Radiation Oncology Quality Standards Committee

Consultant/Speaker Bureau:

1999-2001 VIDA Healthcare Group-Subcommittee for Radiation Therapy 2003-2004 Aventis Pharmaceuticals

5

2005-2006 MedImmune 2011-2012 Spectrum Pharmaceuticals-Speaker 2013-2016 Komen Foundation of Greater Kansas City Board of Directors 2011-present Genomic Health-Speaker (Requested to give over 100 lectures nationally)

Previous Research/Scholarly Activities: Principal Investigator Predictors of therapeutic response and survival in locally advanced breast cancer. A

retrospective study. (IRB: 00020421) Collaborative project with Cook County Hospital. Principle Investigator Biogen-IDEC study (307940/106-20) A Phase III, Open-Label, Prospective, Two-Armed,

Multicenter, Randomized, Group Sequential Study to Evaluate the Efficacy and Safety of Subsequent Treatment with Zevalin (ibritumomab tiuxetan) Study Regimen versus Observation in Patients with Diffuse Large B-cell Lymphoma Who Are in Complete Remission After First-Line CHOP-Rituximab (CHOP-R) Therapy

Principal Investigator A phase II trial of Doxorubicin and Docetaxel in the neoadjuvant treatment of locally

advanced breast cancer with correlation of clinical, molecular and biologic prognostic factors. (ORA-97111002) Collaborative project with Cook County Hospital.

Principal Investigator Predicting response to Anthracycline and Taxane therapies in patients with locally

advanced (stage IIIB) or metastatic breast cancer. (Submitted to IRB 1/2002). Collaborative project with Cook County Hospital.

Principal Investigator Radiation Therapy Oncology Group-RUSH University Co-Investigator The role of PET scanning for definition of treatment fields in non-small cell lung

carcinoma. Co-Investigator A clinical trial of involved field radiation after combination chemotherapy for early stage

Hodgkin’s Disease (HD 9601) [PI: P. Venugopal, M.D.] Co-Investigator A pilot study of combination chemotherapy using Paclitaxel, Ifosfamide, Dexamethasone

and Etoposide (TIDE) for relapsed and refractory Non-Hodgkin’s Lymphoma. (LYM 9701) [PI: S. Adler, M.D.]

Co-Investigator A pilot study of combination chemotherapy using Paclitaxel, Ifosfamide, Mitoxantrone

and Dexamethasone (TIMID) for relapsed and refractory Non-Hodgkin’s Lymphoma. (LYM 9702) [PI: S. Adler, M.D.]

Co-Investigator Combination treatment for aggressive Non-Hodgkin’s Lymphoma including: intensive

induction chemotherapy and very intensive chemotherapy with peripheral blood stem cell rescue. Induction therapy for aggressive Non-Hodgkin’s Lymphoma with a randomized study of Neumega (IL-II) for prophylactic platelet support. (LYM 9910)

Co-Investigator Comparison of the safety and efficacy of Rofecoxib and Phenazopyridine in the

treatment of radiotherapy induced dysuria in cancer patients receiving pelvic radiotherapy. (ORA#: 01020203)[PI: D. Drajer, Pharm D.]

6

Co-Investigator A phase IB study of PEG Hemoglobin in patients receiving palliative fractionated radiation therapy for the treatment of advances solid tumors. [PI: R. Kilbourne, M.D.]

Co-Investigator A dose seeking trial of continuous infusional bromodeoxyuridine and radiation therapy

for locally advanced/recurrent carcinoma of the cervix, vagina and endometrium. (XRT9601)

Co-Principal Investigator Phase I study of subcutaneous administration of recombinant human interleukin-12

(rhIL-12) in patients receiving radiation treatment for inoperable non-small-cell lung cancer. (C97-010108) [Co-PI: P. Bonomi, M.D.]

Co-Investigator Phase 2-3 evaluation of TARGRETIN® capsules in patients with refractory or persistent

early stage cutaneous T-cell lymphoma. (L1069-23 (299)) [PI: M. Tharp, M.D.] Co-Investigator Phase 3 evaluation of TARGRETIN® topical gel in patients with cutaneous t-cell

lymphoma. (L1069T-25 (299)) [PI: M. Tharp, M.D.] Grants: 1996-American Cancer Society Institutional New Investigator Grant 1996-Neopharm Institutional Grant for Clinical Support for Phase I study to evaluate BrDU and XRT in patients with locally advanced cervical cancer (closed) 1997-Berlex Pharmaceutical grant to study interaction of Fludarabine and XRT in in-vitro models (closed) 1998-Rhone-Poulenc Rorer Pharmaceutical grant to support a phase II trial of doxorubicin and docetaxel in the neoadjuvant treatment of locally advanced breast cancer with correlation of clinical, molecular and biologic prognostic factors. 2002-Bears Care Breast Cancer Grant 2003- Bears Care Breast Cancer Grant 2004- Bears Care Breast Cancer Grant EDUCATIONAL HONORS Medical School:

Curator's Scholar University Scholar Award Phi Kappa Phi Honoree Phi Kappa Phi Graduate Fellow Scholarship Omicron Delta Kappa Honoree Alpha Omega Alpha Alumni

Post Graduate: Baylor College of Medicine Veterans Administration Outstanding Service Award-1988 Chief Medical Resident Outstanding Performance Award-1988 Biotechnology Fellowship Grant-1988 UMKC Alumni Research Scholar Award-1990 ASTRO/ESTRO Travel Grant Receipt-1997 PROFESSIONAL ORGANIZATIONS American College of Surgeons Oncology Group Member: Radiation Oncology Subcommittee (2003-2006) Radiation Therapy Oncology Group (RTOG) Member: Translational Research Program Committee (2004-2005)

7

American Society for Therapeutic Radiology and Oncology American Brachytherapy Society American Society of Clinical Oncology American College of Physicians BIBLIOGRAPHY Publications: Burt RK, Gupta-Burt S., Suki WN, Ferguson JJ, Van Buren CT: Reversal of left ventricular dysfunction after renal transplantation. Ann Intern Med 1989 Oct 15: 11(8): 635-640. Reed E, Gupta-Burt S, Litterst CL, and Poirier M: Characterization of the DNA damage recognized by antiserum elicited against cis-diamminedichloroplatinum (II) modified DNA. Carcinogenesis 1990 Dec 11(12): 2117-2121. Poirier MC, Reed E, Litterst CL, Katz D, and Gupta-Burt S: Persistence of platinum-amine-DNA adducts in gonads and kidneys of rats and multiple tissues from cancer patients. Cancer Res 1992 Jan 1, 52(1): 149-153. Pai LH, Swain SM, Reed E, Poirier MC, Gupta-Burt, S, Denicoff AM, and Allegra CJ: Therapy of patients with metastatic breast cancer with 5FU, LCV, and carboplatin (CBDCA). Anti-Cancer Drugs 1992, (3): 463-469. Poirier MC, Gupta-Burt S, Shamkhani H, Tarone RE, and Reed E: Correlation between therapeutic efficacy of platinum-based chemotherapeutic agents and platinum-DNA adduct levels. Env Health Perspect 1993, (99): 149-154. Gupta-Burt S, Shamkhani H, Reed E, Tarone RE, and Allegra CJ, Pai L, and Poirier MC: Relationship between patient response in ovarian and breast cancer and platinum drug-DNA adduct formation. Cancer Epidemiology, Biomarkers and Prevention 1993, May/June; (2): 229-234. Link CJ, Burt RK, Traynor AE, Drobynski WR, Seregina T, Levy JP, Gordon L, Rosen ST, Burns WH, Camitta B, Casper J, Horowitz M, Juckett M, Lawton C, Margolis D, Pietryga D, Rowlings P, Taylor C, Furtado M, Stefka J, Gupta-Burt S, Kaiser H, Vesole, DH: Adoptive immunotherapy for leukemia: donor lymphocytes transduced with the herpes simplex thymidine kinase gene for remission induction. HCTRI 0103. Hum Gene Ther 9(1): 115-34, Jan 1998. Coon JS, Marcus E, Gupta-Burt S, Seelig S Jacobson K, Chen S, Renta V, Fronda G, Preisler H, Amplification and Overexpression of Topoisomerase IIα Predict Response To Anthracycline-based Therapy in Locally Advanced Breast Cancer. Accepted for publication in Clinical Cancer Research 2002. Marcus E, Gupta- Burt S, John Coon J, Holden C , Shiomoto G, McDunn S, Kaspar C, Preisler H. The Safety And Efficacy Of Docetaxel And Doxorubicin In The Neoadjuvant Treatment Of Locally Advanced Breast Cancer In An Urban Underserved Population. Submitted 2004 Gupta- Burt S, Marcus E , John Coon J, Holden C , Shiomoto G, McDunn S, Kaspar C, Preisler H The Role of Positron Emission Tomography in Disease Response Assessment in Patients with Locally Advanced Breast Cancer. Submitted 2005. Gupta- Burt S, Marcus E , John Coon J, Holden C , Shiomoto G, McDunn S, Kaspar C, Preisler H Positron Emission Tomography Correlation with Molecular and Biologic Markers inPatients with Locally Advanced Breast Cancer. Submitted 2005.

8

Book Chapters and Invited Publications: Poirier MC, Weston A, Gupta-Burt S, and Reed E: Measurement of DNA Adducts by Immunoassay. In: DNA Damage and Repair in Human Tissues Sutherland, BM and Woodhead, AD (Eds), Plenum Press, New York, 1990; l-ll. Poirier M, Weston A, Gupta-Burt S, Reed E: Measurements of DNA Adducts by Immunoassays. (Review) Basic Life Sciences 1990, 53:1-11. Poirier MC, Gupta-Burt S, Litterst CL and Reed E: Detection of Cisplatin-DNA adducts in humans. In: Immunoassays for Monitoring Human Exposure to Toxic Chemicals Vanderlaan M. (Ed.), American Chemical Society Books, Washington, DC, 300-307, 1990. Poirier MC, Shamkhani H, Reed E, Tarone RE, and Gupta-Burt S: DNA adducts induced by platinum drug chemotherapeutic agents in human tissues. In: Progress in Clinical and Biological Research John Wiley and Sons, Inc., New York, New York, 1992 374:197-212. Gupta-Burt S, and Okunieff P: Total Body Irradiation. In: House Officers' Manual for Bone Marrow Transplantation. Burt, R, Deeg, J, Santos, G(eds) R G Landes Co, Austin, TX Chapter4.2 109-122, 1996. Gupta-Burt S MCM-SAP Multidisciplinary Cancer Management Self-Assessment Program Cancers of the Lung Saxena, V (ed) Edition 1, Professional Evaluation, Inc., 1999. Gupta-Burt S, Coon J, Ali A, Preisler H, Marcus E: Correlation of estrogen receptor status and positron emission tomography in the assessing the pathologic response in patients with LABC treated with neoadjuvant doxorubicin and docetaxel chemotherapy. Cancer Conference Highlights Vol 4 No 6 July 2000. Published Abstracts: Reed E, Gupta-Burt S, Yuspa S H, Tarone R, Ozols RF, Katz D and Poirier MC: Platinum-DNA adduct levels in malignant and non-malignant tissues of cancer patients correlate with disease response. AMA Fed. Clin. Res 1988 Pendyala L, Arakali AV, Sansone P, Cowens JW, Gupta-Burt S, Poirier MC, and Creaven, PJ: DNA binding of iproplatin (IP) and its metabolite cis-dichloro-bis isopropylamine platinum II (CIP). Proc. Am. Assoc. Cancer Res 1988. Reed E, Gupta-Burt S, Katz D, and Poirier MC: Platinum-DNA adduct measured at autopsy in multiple human tissues. Proc. Am. Assoc. Cancer Res 30: 276 (ABS. 1099), 1989. Gupta-Burt S, Shamkhani H, Reed E, Tarone RE and Poirier MC: Correlation between cisplatin-DNA adduct levels and positive clinical response in cancer patients. Proc. Am. Assoc. Cancer Res 32: 412 (Abs. 2448), 1991. Poirier MC, Gupta-Burt S, Shamkhani H, Tarone RE, and Reed E: Correlation between therapeutic efficacy of platinum-based chemotherapeutic agents and platinum-DNA adduct levels. The International Meeting on Biomonitoring and Susceptibility Markers in Human Cancer. Kona, HI, 1991. Shahidi H, Gregory SA, Showel JL, Venugopal P, Riley MB, Foster GS, Recine DC, Gupta-Burt S: Two Cycles of Mitoxantrone, Bleomycin, Vinblastine, and Dexamethasone (MBVD) Followed by Stage Appropriate Therapy for Hodgkin’s Disease: Preliminary Results From a Pilot Study. Blood vol 88 (supp 1 part 2) p193b December 1996.

9

Sharma M, Gupta-Burt S, Faber P, Racine D, Bonomi P: Broncho-Pulmonary Toxicity in Stage III Non Small Cell Lung Cancer Patients Treated with Taxol Containing Chemotherapy and Concurrent Preoperative or Definitive Radiation Therapy. IJROBP Vol 39, No 2 Supplement p312 1997. Nguyen C, Gupta-Burt S, Silverton C, Cummings M, and Galante J: Preliminary Results of a Randomized Trial Comparing 400cGy vs 700 cGy As An Adjunct to Prevent Heterotopic Ossification After Total Hip Arthroplasty IJROBP Vol 39, No 2 Supplement p154 1997. Chopra H, Sivaraman S, Gupta-Burt S, Marcus E, Coon J, Cobleigh M, Cass L, Spaulding D, Venugopal P, and Preisler H: Determination of Labeling Index (LI) by In situ Hybridization (ISH) for Histone H3 mrna in Locally Advanced Breast Cancer With Correlation to Clinical Outcome. Breast Cancer Research and Treatment 50(3): 282, 1998. Venugopal P, Gupta-Burt S, Slivnick D, Adler S, Gregory SA, Jajeh A, Hall T and Preisler HD: Interferon (IFN)-based combination chemotherapy in chronic myelogenous leukemia: Increasing dose intensity improves response. Blood 92 (Suppl 1)(part 2 of 2):250b, 1998. Marcus E, Gupta-Burt S, Shiomoto G, Holden C, Coon J, Frommel T, Bork J, Priesler H: The safety of doxorubicin and docetaxel in a phase II study of the neoadjuvant treatment of locally advanced breast cancer. Program/Proceedings American Society of Clinical Oncology 18: 98a, 1999. Gupta-Burt S, Marcus E, Coon J, Fronda G, Holden C, Preisler H, Ali A: The role of positron emission tomography in the assessment of pathologic response to neoadjuvant chemotherapy with Adriamycin and Taxotere in patients with locally advanced breast cancer. Presented at ECCO annual meeting 1999. Marcus E, Shiomoto G, Holden C, Lowenthal M, Hill D, Frommel T, Bork J, Coon J, Preisler H, Gupta-Burt S: The efficacy of doxorubicin and docetaxel (taxotere) in a phase II trial of neoadjuvant treatment of locally advanced breast cancer. Breast Cancer Research and Treatment 57(1): 69, 1999. Gupta-Burt S, Coon J, Lowenthal M, Holden C, Preisler H, Ali A, Marcus E: Correlation of estrogen receptor status and positron emission tomography in assessing pathologic response in patients with locally advanced breast cancer treated with neoadjuvant doxorubicin and docetaxel chemotherapy. Breast Cancer Research and Treatment 57(1): 57, 1999. Vallow L, Shahidi H, Gregory SA, Deutsch T, Rubenstein J and Gupta-Burt S: The role of radiation therapy in orbital lymphoma. Blood 94 (Suppl 1)(Part 2 of 2): 268b-269b, 1999. O'Brien TM, Anupama R, Venugopal P, Kaplan EH, Gupta-Burt S, Foster GS and Gregory SA: A novel approach to the treatment of early stage Hodgkin's disease with mitoxantrone-based regimen followed by involved field radiotherapy. Blood 94(Suppl 1)(Part 2 of 2): 265b,1999. Bryant D, Gupta-Burt S, Gregory SA, Simpson D and Kaizer H: The role of involved field radiation therapy (IFRT) for patients with intermediate grade NHL receiving bone marrow transplantation. Blood 94 (Suppl 1)(Part 2 of 2): 375b, 1999. Coon JS, Marcus E, Gupta-Burt S, Shen M, Fronda G, Holden C, Preisler H: C-Erb-2 Expression Predicts Response To Doxorubicin And Docetaxel In Locally Advanced Breast Cancer. Proc. Am. Assoc. Cancer Res. vol 41 p331 2000.

10

Marcus E, Coon J, Holden C, Chen S, Fronda G, Preisler H, Gupta-Burt S: Predictors Of Response To Doxorubicin And Docetaxel In Locally Advanced Breast Cancer. Program/Proceedings American Society of Clinical Oncology vol 19; 655a, 2000. Gupta-Burt S, Marcus E, Coon J, Holden C, Frommell T, Preisler H, Ali A: The Correlation of Pathologic Response with Positron Emission Tomography in Patients with Locally Advanced Breast Cancer Treated with Neoadjuvant Chemotherapy. Radiotherapy and Oncology 56 (supp1) S41 September 2000. Chang JY, Shao R, Xia W, Gupta-Burt S, Saxena VA, Hung MC: Systemic Gene Therapy of HER-2/neu-overexpressing Breast Cancer Using Radiation Sensitizer E1A gene. IJROBP Vol 48, No 3 Supplement p188 abstract 154 2000. Vallow L, Gupta-Burt S, Gregory S, Rubeinstein J, Deutch T: The Role of Radiation Therapy in Orbital Lymphoma. Radiotherapy and Oncology 56(supp1) S144 September 2000. Gupta-Burt S, Deshpande C, Coon J, Sivaraman S, Preisler H, Ali A, Marcus E: The Correlation of Histone H3 Labeling Index and Post Chemotherapy Pet Scan in Patients with LABC Treated with Neoadjuvant Doxorubicin and Docetaxel. Breast Cancer Research and Treatment 64(1):70 Abstract 259 November 2000. Coon J S, Marcus E, Gupta-Burt S, Seelig S, Jacobson K, Fronda G, Preisler H: Amplification of Topoisomerase IIα or C-erbB-2 Predicts Response To Doxorubicin And Docetaxel In Locally Advanced Breast Cancer. Breast Cancer Research and Treatment 64(1): 78 Abstract 309 70 November 2000. Marcus E, Holden C, Coon J, H Preisler S and Gupta-Burt S: Improving Adherence To Breast Cancer Treatment In Public Hospital Patients Presenting With Advanced Disease. Breast Cancer Research and Treatment 64(1):130 Abstract 558 November 2000. Coon JS, Marcus E, Gupta-Burt S, Seelig S, Jacobson K, Renta V, Fronda G, Preisler H.: Amplification Of Topoisomerase 2alpha Or C-ErbB-2 Predicts Response To Anthracycline Based Therapy In Locally Advanced Breast Cancer. Proc American Assoc Cancer Res 42:119, 2001. Chang JY, Xia W, Shao R, Gupta-Burt S, Saxena VA, Hung MC: Radiation Sensitization of Her-2/NEU Overexpressing Head and Neck Cancer by E1A Gene Therapy. Radiology (suppl) 221:178-179 November 2001 Coon JS, King W, Marcus E, Gupta-Burt S, Renta V, Preisler H, Seelig S. Array-Based Comparative Hybridization Reveals Differential Gene Patterns According to ChemotherapyResponse in Locally Advanced Breast Cancer. Submitted for presentation at the American Association for Cancer Research Annual Meeting 2002. Other Abstracts: Poirier MC, Gupta-Burt S, Shamkhani H, and Reed E: Utilization of an anti cisplatin-DNA enzyme linked immunosorbent assay. Sixth International Conference on Platinum and Other Metal Coordination Compounds In Cancer Chemotherapv. San Diego, CA, January 1991. Poirier MC, Gupta-Burt S, Shamkhani H, Reed E, Rothman N, and Strickland P: DNA adduct formations in human tissues due to medicinal or occupational exposures. Environmental Carcinogenesis and its Prevention: The Head and Neck Cancer Model. Hershey, PA October 1991. Gupta-Burt S, Shamkhani H, Reed E, Tarone R and Poirier MC: Correlation between cisplatin-DNA adduct levels in clinical response in cancer patients. NIH Research Day, September 24, 1991.

11

Gupta-Burt S, Reed E, Tarone RE, Shamkhani H and Poirier MC: Correlation of blood cell cisplatin-DNA adducts measured by ELISA with positive clinical outcome in breast, colon and ovarian cancer patients. Sixth International Conference on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. San Diego, CA January 1991. Poirier MC, Rothman N, Strickland PT, Gupta-Burt S, Reed E, Shamkhani H, and Tarone RE: DNA adduct determination in human tissues and blood cell DNA. Mary Lasker Conference on Molecular Epidemiology of Cancer Risk Assessment. Sarasota, FL April 1991. Blazek ER, Taw I, and Gupta-Burt S: Fractionated Irradiation Studies of Interferon Beta as a Radiosensitizer and an Antiproliferative for A549 Non Small Cell Lung Cancer Cells. Radiation Research Meeting, Chicago, IL, April 1996. Blazek ER, Gupta-Burt S, Alt S, Zhou S, Subbaiah S: Effective Survival of Human Non-small Cell Lung Cancer Cell Lines with Concurrent Fractionated Irradiation and Exposure to Cisplatin and/or Interferon-Beta. Tenth International Conference on Chemical Modifiers of Cancer Treatment. Clearwater, FL. 1997. Blazek E, Gupta-Burt S, Bryant D, Subbaiah S: Sensitization by Recombinant Interferon-beta of the Human Nonsmall Cell Lung Cancer Cell Line A549 to Killing by Radiation, Cisplatin, or Carboplatin. Radiologic Society of North America Annual Meeting. Chicago, Il December, 1998. Gupta-Burt S, Vallow L, Coon J, Preisler H, Ali A, Marcus E: PET Scan Assessment of Axillary Lymph Node Status In Patients With LABC Treated With Neoadjuvant Doxorubicin And Docetaxel. 2nd Annual Lynn Sage Breast Cancer Symposium, Chicago, IL September, 2000. Gupta-Burt S, Coon J, Mishra C, Holden C, Preisler H, Ali A, Marcus E: The Correlation of Estrogen Receptor Status, Her2neu Expression and Positron Emission Tomography in the Assessment of Pathologic Response in Patients with Locally Advanced Breast Cancer Treated with Neoadjuvant Doxorubicin and Docetaxel Chemotherapy. EBCC-2 (European Breast Cancer Conference-2), Belgium, September 2000. Marcus E, Gupta-Burt S, Preisler H, Coon J.: C-Erbb2 Over-Expression Measured By Immunohistochemistry (IHC) May Not Correlate With Gene Amplification Measured By Florescence In Situ Hybridization (FISH) On Needle Core Biopsy Specimens. Society of Surgical Oncology 54th Annual Cancer Symposium, Washington DC March 15-18, 2001. Buch S, Zimmer J, Gupta-Burt S, Chu J, Saxena V.: Feasibility Study for Implementation of Partial Lung Blocks for Total Body Irradiation. RUSH Research Day Chicago IL April 2001. Deshpande CG, Gupta-Burt S, Con J, Sivarman S, Preisler H, Marcus E. Correlation of LI and Her2-Neu Expression as Predictors of Response in Locally Advanced Breast Cancer. 3nd Annual Lynn Sage Breast Cancer Symposium, Chicago, IL October, 2001. Academic Invited Lectures and Presentations: Gupta-Burt, S: Molecular evaluation of cisplatinum DNA interaction: Clinical correlates. Alumni Research Award Presentation. UMKC Research Symposium,Kansas City, MO April 1990. Gupta-Burt, S: Cis-Platinum DNA Interaction and Radiosensitivity. Loyola-Hines University Medical Center, Radiation Oncology Department, Chicago, IL 1994.

12

Gupta-Burt, S: Recent Advances in the Management of Locally Advanced or Unresectable Non-Small Cell Lung Cancer, Sixth Annual Malnati Symposium, Oncology: A Year in Review. Northwestern University Medical School, Chicago, IL June 1995. Gupta-Burt, S: Effect of Radiation on the Formation of Cis-Platinum DNA-Adducts. Radiation Oncology Department, Medical College of Wisconsin, Milwaukee, WI June 1994. Gupta-Burt, S: Fundamentals of Total Body Irradiation Northwestern University Medical School, Department of Hematology-Oncology, Chicago, IL August 1999 Gupta-Burt, S: The Role of Radiation Therapy in the Management of Locally Advanced or Unresectable Non-Small Cell Lung Cancer, Chest Tumor Conference, Cook County Hospital, Chicago, IL, May 1996. Gupta-Burt, S: Chu, J, and Blazek, E, Total Body Irradiation: Biology, Physics and Clinical Implications, Mid-America Radiation Therapy Forum, Chicago Radiologic Society, October 1996. Gupta-Burt, S: CTCL: The Role of Total Skin Electron Beam Therapy, Department of Dermatology Conference, RUSH Presbyterian St Luke’s Hospital, Chicago, IL December 1996. Gupta-Burt, S: Principles of Total Body Irradiation. RUSH-Presbyterian-St. Luke's Medical Center, Medical Oncology Grand Rounds, Chicago, IL November 1995. Gupta-Burt, S: Recent Advances in Radiation Therapy with Locally Advanced or Unresectable Head and Neck Cancer, RUSH-Presbyterian-St. Luke's Medical Center, Department of Otolaryngology, Chicago, IL November, 1995. Gupta-Burt, S: Principles of Total Body Irradiation. RUSH-Presbyterian-St. Luke's Medical Center, Medical Oncology Grand Rounds, Chicago, IL November 1995. Gupta-Burt, S: Recent Advances in Radiation Therapy with Locally Advanced or Unresectable Head and Neck Cancer, RUSH-Presbyterian-St. Luke's Medical Center, Department of Otolaryngology, Chicago, IL November 1995. Gupta-Burt, S: The Role of Radiation Therapy in the Management of Locally Advanced or Unresectable Non-Small Cell Lung Cancer, Chest Tumor Conference, Cook County Hospital, Chicago, IL May 1996. Gupta-Burt, S: Chu, J., and Blazek, E., Total Body Irradiation: Biology, Physics and Clinical Implications, Mid-America Radiation Therapy Forum, Chicago Radiologic Society, Chicago, IL October 1996. Gupta-Burt, S: CTCL: The Role of Radiation Therapy for Cutaneous T-Cell Lymphoma, Department of Dermatology Conference, RUSH Presbyterian St Luke’s Hospital, Chicago, IL December 1996. Gupta-Burt, S: Fundamentals of Total Body Irradiation. Northwestern University Medical School, Department of Hematology-Oncology, Chicago, IL August 1996. Gupta-Burt, S: The Role of Radiation Therapy in Breast Cancer, Cook County Medical Grand Rounds, Chicago, IL 1999. Gupta-Burt, S: Locally Advanced Breast Cancer in the African American Women, Y-ME National Symposium, Chicago, IL April 1999.

13

Gupta-Burt, S: Radiation Therapy Techniques in Breast Conservation Therapy, University of Illinois Women’s Health Conference, Chicago, IL April 1999. Gupta-Burt, S: The Role of Radiation Therapy in Breast Cancer, Bears Care Foundation, Standard Club, Chicago, IL June 1999. Gupta-Burt, S: CisDDP DNA Adducts and Radiosensitization, Department of Radiation Therapy Conference, University of Utah, Salt lake City, UT June 2000. Gupta-Burt, S: Principles of Radiation Therapy Techniques Used in Skin Cancer, Department of Dermatology Conference, RUSH Presbyterian St Luke’s Hospital, Chicago, IL December 2000. Gupta-Burt, S: Fundamentals of Total Body Irradiation. Department of Radiation Oncology, University of Kansas, KU Medical Center, Kansas City, KS March 2001. Gupta-Burt, S: Total Skin Electron Beam Therapy for CTCL. Department of Dermatology Grand Rounds, RUSH University Medical Center, Chicago, IL 2002. Gupta-Burt, S: The Role of Radiation Therapy for Non Hodgkin’s Lymphoma. Section of Hematology Lecture Series, RUSH University Medical Center, Chicago, IL 2003. Gupta-Burt, S: Radiation Therapy Principles in the Treatment of Skin Cancer. Department of Dermatology Grand Rounds, RUSH University Medical Center, Chicago, IL 2003. Gupta-Burt, S: The Current State of the Art in Radiation Therapy for Lung Cancer, Lung Cancer Symposium, Philip Bonomi, Course Director, Chicago, IL 2004. Gupta-Burt, S: Radiation Treatment Planning Strategies for Lymphoma. Department of Medicine Hematology Grand Rounds, RUSH University Medical Center, Chicago, IL 2004.

14

Supplement A Hospital Affliations